Platelet

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Jeudi, mai 5, 2022
Intracranial hemorrhage, Drug development, Fortnight, Immunoglobulin G, Splenectomy, Safety, GMG, Depression, Bleeding, Prevalence, Anxiety, Administration, SEC, Risk, Forward-looking statement, Euronext, Acetylcholine receptor, NASDAQ, Neonatal Fc receptor, Patient, Bruise, Incidence, Rituximab, ITP, Mental health, Research, SAN, Platelet, L, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, International Working Group on Neurotransmitter Related Disorders, Time, Immune thrombocytopenic purpura, HKEX, Degenerative disease, COVID-19, Fear, GLOBE, Steroid, Immunoglobulin therapy, Coronavirus, Diagnosis, Anemia, History, Adult, Health, IWG, Infection, Autoantibody, Medical imaging, Fine chemical, Pharmaceutical industry, Vaccine, Security (finance)

SHANGHAI, China and SAN FRANCISCO and CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the company’s partner argenx (Euronext & Nasdaq: ARGX) reported positive data from the Phase 3 ADVANCE trial of VYVGART® (efgartigimod alfa-fcab).

Key Points: 
  • In adults with primary ITP, ADVANCE met its primary endpoint demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • ADVANCE is the first Phase 3 clinical trial of a neonatal Fc receptor (FcRn) blocker in ITP.
  • Additional secondary endpoint data from the ADVANCE trial are consistent with primary and secondary platelet-derived endpoints and provide additional context on metrics that often drive treatment decisions.
  • The Phase 3 ADVANCE trial was a randomized, double-blind, placebo-controlled, multicenter, global trial evaluating the efficacy and safety of VYVGART in adult patients with chronic or persistent primary ITP.

The Worldwide Blood Collection Devices Industry is Expected to Reach $8 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Mercredi, mai 4, 2022
Health, General Health, Laboratory, Rupture, Oxygen, World Health Organization, Coagulation, Patient, Collection, Platelet, Coronavirus, DVA, Method, Anemia, Blood, Leukemia, WB, Hospital, Adoption, Degenerative disease, Health, Hematology, Lymphatic system, Level, CAGR, Infection, ETDA, Application, Giant platelet disorder, Risk, Diagnosis, Medical device

The Global Blood Collection Devices Market size is expected to reach $8 billion by 2027, rising at a market growth of 6.2% CAGR during the forecast period.

Key Points: 
  • The Global Blood Collection Devices Market size is expected to reach $8 billion by 2027, rising at a market growth of 6.2% CAGR during the forecast period.
  • Legitimate blood collection and on-time processing by skilled staff utilizing efficient devices are required in order to assure test reliability.
  • The cost involved in initial investment for the adoption of automated blood collection by the use of apheresis devices involves high costs as compared to blood collection.
  • The higher cost of these devices is leading to the lower adoption of automated blood collection devices.

Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia

Retrieved on: 
Mardi, mai 3, 2022
United Kingdom, COVID-19, LSD1, MF, Bone marrow, Private Securities Litigation Reform Act, EHA, European Medicines Agency, EMA, Pharmacokinetics, GLOBE, Food and Drug Administration, Food, Safety, Patient, Trial of the century, Review, ASH, FDA, Cancer, Annual report, Pancreatic serous cystadenoma, Compliance, WBC, MAF, Facebook, Lists of disasters, Priority, Fast Track, Ageing, Ruxolitinib, LinkedIn, Pandemic, ET, Society, Sale, Blood, HIV disease progression rates, Growth, Platelet, Pharmaceutical industry, Imago

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that enrollment has been completed for the Phase 2 clinical study of bomedemstat for the treatment of essential thrombocythemia (ET) with 73 patients enrolled, exceeding the initial target enrollment of 60 patients. This study is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of bomedemstat, an oral lysine-specific demethylase 1 (LSD1) inhibitor, in patients with ET who have failed at least one standard therapy.

Key Points: 
  • We are pleased to have completed enrollment in our global Phase 2 clinical study of bomedemstat for the treatment of patients with ET and gratified to have exceeded our initial enrollment target.
  • I thank the patients who enrolled in the trial, the clinical investigators and Imago team who worked tirelessly to advance the study to this point.
  • We will present interim data from this study at the June EHA meeting and results from the completed study later this year.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia ( NCT04254978 ) and myelofibrosis ( NCT03136185 ).

CTI BioPharma to Report First Quarter 2022 Financial Results on May 12, 2022

Retrieved on: 
Jeudi, avril 28, 2022
CTIC, Patient, Ruxolitinib, FDA, Vera, ID, JAK1, Acquisition, Platelet, Webcast, NASDAQ, JAK2, Thrombocytopenia, CTI, Pharmaceutical industry

SEATTLE, April 28, 2022 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022, after the close of the U.S. financial markets.

Key Points: 
  • SEATTLE, April 28, 2022 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022, after the close of the U.S. financial markets.
  • Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m.
  • To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 7291915.
  • A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com .

Cerus Corporation Announces Multi-Year Contract for the INTERCEPT Blood System for Platelets with the American Red Cross

Retrieved on: 
Lundi, avril 25, 2022
Medical Supplies, Medical Devices, Health, Infectious Diseases, Hospitals, Biotechnology, Red Cross, International Red Cross and Red Crescent Movement, Red, Cryoprecipitate, American Red Cross, Bleeding, Leadership, Hospital, Patient, LinkedIn, Corporation, Platelet, Factor, Plasma, Nasdaq, Transfusion medicine, World Red Cross and Red Crescent Day, Safety, Physician, FDA, CERS, Partnership, Transfusion transmitted infection, Blood product, Pharmaceutical industry, Society of Spanish Researchers in the United Kingdom (SRUK/CERU)

Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets.
  • Under the terms of this contract, Cerus will continue to supply the Red Cross the INTERCEPT Blood System used to produce pathogen reduced platelets, in support of the Red Cross goal to transition toward a full pathogen reduced platelet supply for its hospital customers across the U.S.
  • Cerus is proud of our long history of collaborating with the Red Cross, as they have played a critical role in the deployment of the INTERCEPT Blood System to safeguard the U.S. blood supply, stated William Obi Greenman, Cerus president and chief executive officer.
  • Thanks to their leadership and commitment to blood safety, the Red Cross is now the largest producer of INTERCEPT treated blood components in the world.

Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine

Retrieved on: 
Jeudi, avril 14, 2022
Patient, EMA, Annual report, Medicine, BTK, The New England Journal of Medicine, Nausea, Pharmacokinetics, Atopic dermatitis, COVID-19, Degenerative disease, Asthma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Social responsibility, Research, Ageing, Bleeding, Food, Incidence, Science, Private Securities Litigation Reform Act, Fast track (FDA), Inflammation, Death, Immunoglobulin G, Hospital, SAN, Intellectual property, Trial of the century, Platelet, Immune system, SNY, ITP, SEC, Forward-looking statement, Massachusetts General Hospital, Thrombocytopenia, Safety, FDA, Quality of life, Harvard Medical School, Risk, AMF, Diarrhea, Form 20-F, Fatigue, Pharmaceutical industry, Vaccine, Sanofi

Results demonstrate treatment with rilzabrutinib led to a rapid and durable increase in platelet count and support an acceptable safety profile.

Key Points: 
  • Results demonstrate treatment with rilzabrutinib led to a rapid and durable increase in platelet count and support an acceptable safety profile.
  • Despite advances in treatment options over the years, some patients remain refractory to existing therapies and durable remission remains elusive.
  • ITP is an acquired autoimmune blood disorder characterized by low platelet count (thrombocytopenia) resulting from immune-mediated platelet destruction and impairment of platelet production.
  • The global Phase 1/2 adaptive, open-label, dose-finding study evaluated rilzabrutinib in 60 people with ITP with a median age of 50 years (range, 19-74).

Horizon Technology Finance Leads $15 Million Venture Loan Facility to Secure Transfusion Services

Retrieved on: 
Jeudi, mars 17, 2022
Private Securities Litigation Reform Act, Company, Method, NASDAQ, STS, Hospital, U.S. Securities and Exchange Commission, Quality of life, Platelet, Technology, Safety, Hope, Securities & Exchange Commission of Pakistan, Income, Solution, Patient, Security (finance), Horizon

FARMINGTON, Conn., March 17, 2022 /PRNewswire/ --Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today it closed a $15 million venture loan facility to Secure Transfusion Services, Inc. ("STS"), of which Horizon funded $5 million of the initial $10 million draw, and a private investment vehicle managed by Horizon Technology Finance Management LLC, Horizon's adviser, funded $5 million.

Key Points: 
  • FARMINGTON, Conn., March 17, 2022 /PRNewswire/ --Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today it closed a $15 million venture loan facility to Secure Transfusion Services, Inc. ("STS"), of which Horizon funded $5 million of the initial $10 million draw, and a private investment vehicle managed by Horizon Technology Finance Management LLC, Horizon's adviser, funded $5 million.
  • STS is backed by prominent firms including Cerus Corporation and OneBlood, and will use the loan proceeds for general growth and working capital purposes.
  • Horizon Technology Finance Corporation (NASDAQ: HRZN) is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries.
  • Secure Transfusion Services(STS) aims to increase the quality, safety, and availability of transfusable blood components, starting first with apheresis platelets.

China Clopidogrel Investigation Market Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Lundi, mars 7, 2022
Health, Pharmaceutical, Salubris Pharmaceuticals, Chuang Song Zong Pharmaceutical Co., Ltd., Hangzhou, Platelet, Pulitzer Prize for Investigative Reporting, Dosage form, CAGR, Animal, Fine chemical, Generic drug, Pharmaceutical industry, Sanofi, Clopidogrel, Clopidogrel

The "Investigation Report on Chinese Clopidogrel Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on Chinese Clopidogrel Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • In addition to Sanofi, the other main manufacturers of Clopidogrel in the Chinese market are Salubris Pharmaceuticals, Lepu Pharmaceutical, and CSPC Ouyi Pharmaceutical.
  • According to this market research, sales revenue of Clopidogrel in China has been decreasing since 2018, sales value of Clopidogrel in China was approximately CNY680 million, and the CAGR is -21.9% in 2016 to 2020.
  • Nevertheless, as the antithrombotic market keeps expanding, Clopidogrel will still have considerable annual sales in the short term.

VONJO™ (pacritinib) Now Approved for the Treatment of Adults with Intermediate or High-Risk Primary or Secondary Myelofibrosis with a Platelet Count Below 50 x 109/L

Retrieved on: 
Vendredi, mars 4, 2022
Oncology, Health, Genetics, General Health, Radiology, Pharmaceutical, Biotechnology, Thrombocytopenia, Specialty pharmacy, Bone marrow, Regulation of tobacco by the U.S. Food and Drug Administration, Vera, Lymphatic system, Patient, Adult, Food, Aplastic anemia, Biopharma LLC, Myeloproliferative neoplasm, FDA, United, Survival, Splenomegaly, Haematopoiesis, Fatigue, Ruxolitinib, Leukemia, NCT, Hepatomegaly, Physician, Platelet, CTI, Medical imaging

Onco360 is honored to become a specialty pharmacy provider for VONJO patients, said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • Onco360 is honored to become a specialty pharmacy provider for VONJO patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • We are committed to supporting the highly specialized needs of myelofibrosis patients with thrombocytopenia and their physicians across the United States.
  • Approximately 1.5 myelofibrosis cases per 100,000 people are diagnosed annually in the United States.
  • The FDAs approval of VONJO is based upon the results of the PERSIST-2 clinical trial (NCT 02055781).

CTI BioPharma to Present at the Cowen 42nd Annual Healthcare Conference

Retrieved on: 
Mercredi, mars 2, 2022
Thrombocytopenia, Vera, Platelet, Patient, JAK2, FDA, CTIC, Ruxolitinib, Conference, Acquisition, JAK1, NASDAQ, CTI, Pharmaceutical industry

SEATTLE, March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m.

Key Points: 
  • SEATTLE, March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m.
  • CTI has one FDA-approved product VONJOTM (pacritinib), a JAK2 and IRAK1, that spares JAK1.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • VONJOTM is a trademark of CTI BioPharma Corp.